Skip to main content

Sandler Laura Lee's Form 4 filing

Oruka Therapeutics, Inc. (ORKA) · filed Jul 1, 2026

Accession no.
0000907654-26-000069
Filed
Jul 1, 2026, 7:58 PM ET
Trade date
Jul 1, 2026
Filing delay
Same day
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $472.1K. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Sandler Laura LeeCIK 0002075401Officer (Chief Operating Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 1, 2026Common StockMOption exerciseAcquired+5,000$7.80+$39,000241,384Direct
Jul 1, 2026Common StockSSaleDisposed−2,237$93.85−$209,932.83239,147Direct
Jul 1, 2026Common StockSSaleDisposed−2,263$94.75−$214,409.75236,884Direct
Jul 1, 2026Common StockSSaleDisposed−500$95.47−$47,736236,384Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jul 1, 2026Common StockMOption exerciseDisposed−5,000$0.00$079,996Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)